TP53 and Merkel cell skin cancer: KRT-232 (navtemadlin), an MDM2 inhibitor, demonstrated efficacy in phase 1b/2 trials (NCT03787602) for p53 wild-type MCC patients, particularly those resistant to anti-PD1/PD-L1 therapy.